Crystal Structure of a Human IaB Kinase ß Asymmetric Dimer
News Jun 27, 2013
Phosphorylation of inhibitor of nuclear transcription factor B (IB) by IB kinase (IKK) triggers the degradation of IB and migration of cytoplasmic B to the nucleus where it promotes the transcription of its target genes. Activation of IKK is achieved by phosphorylation of its main subunit, IKK at the activation loop sites. Here we report the 2.8 Å resolution crystal structure of human IKKhIKK which is partially phosphorylated and bound to the staurosporine analog K252a. The hIKK protomer adopts a trimodular structure that closely resembles that from Xenopus laevis (xIKK: an N-terminal kinase domain (KD), a central ubiquitinlike domain (ULD), and a C-terminal dimerization domain (SDD). Although hIKK and xIKK utilize a similar dimerization mode, their overall geometries are distinct. In contrast to the structure resembling closed shears reported previously for xIKK hIKK exists as an open asymmetric dimer in which the two KDs are further apart, with one in an active and the other in an inactive conformation. Dimer interactions are limited to the C-terminal six-helix bundle that acts as a hinge between the two subunits. The observed domain movements in the structures of IKK may represent transphosphorylation steps that accompany IKK activation.
This article was published online in The Journal of Biological Chemistry and is free to access.
Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug DiscoveryNews
Scientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.READ MORE
Crystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity TreatmentNews
An international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
8th International Conference on Drug Discovery and Therapy
Feb 13 - Feb 15, 2019